Oncology + Eternal = Oncternal

We are committed to advancing novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Our scientific approach focuses on promising, yet untapped biological pathways implicated in cancer generation or progression.

Our Pipeline

Oncology + Eternal = Oncternal

We are committed to advancing novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Our scientific approach focuses on promising, yet untapped biological pathways implicated in cancer generation or progression.

Our Pipeline

Oncology + Eternal = Oncternal

We are committed to advancing novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Our scientific approach focuses on promising, yet untapped biological pathways implicated in cancer generation or progression.

Our Pipeline

Welcome to Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments to treat hematological malignancies and prostate cancer across multiple modalities.

About Our Science
Meet Our Team

RECENT NEWS

May2023

4

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
Apr2023

27

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results

We are enrolling patients:

With Relapsed or Refractory B-Cell Malignancies for a Phase 1/2 study of ONCT-808, our ROR1-Targeting Autologous Cell Therapy (NCT05588440)

Participate in Our Trials